Long‐duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half‐life
- 12 March 2001
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 16 (2) , 301-305
- https://doi.org/10.1002/mds.1070
Abstract
A possible reason why levodopa induces a sustained, stable motor benefit during the first months to years of therapy may be its long duration of action. This long‐duration effect may be due either to a presynaptic storage mechanism or to postsynaptic pharmacodynamic changes. We previously reported that the dopamine agonist ropinirole induced a long‐duration response (LDR) in levodopa‐naive patients with Parkinson's disease. In this study, we investigated motor responses to the short half‐life dopamine agonist lisuride in a group of levodopa naive parkinsonian patients. Once lisuride reached its maximum effect, it was substituted, in randomized order, with placebo. Neither investigators nor patients knew when the active drug was switched to placebo. When patients were switched from lisuride to placebo, their Unified Parkinson's Disease Rating Scale (UPDRS) motor scores and tapping test and screw scores declined to baseline values within a mean 9.0 ± 1.9 days. The results confirmed that, like ropinirole and levodopa, the short‐acting dopamine agonist lisuride induces a long‐duration response, probably due to postsynaptic changes. © 2001 Movement Disorder Society.Keywords
This publication has 11 references indexed in Scilit:
- Apomorphine responses in parkinson's disease and the pathogenesis of motor complicationsNeurology, 1997
- The response to levodopa in parkinson's disease: Imposing pharmacological law and orderAnnals of Neurology, 1996
- The subacute levodopa test for evaluating long‐duration response in parkinson's diseaseAnnals of Neurology, 1995
- Long-duration response to levodopaNeurology, 1995
- Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's diseaseAnnals of Neurology, 1992
- Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's diseaseAnnals of Neurology, 1990
- [76Br]Bromolisuride: A new tool for quantitative in vivo imaging of D-2 dopamine receptorsEuropean Journal of Pharmacology, 1986
- The pharmacokinetics and biotransformation of14C-Lisuride hydrogen maleate in rhesus monkey and in manEuropean Journal of Drug Metabolism and Pharmacokinetics, 1984
- The pharmacokinetics of lisuride hydrogen maleate in rat, rabbit and rhesus monkeyEuropean Journal of Drug Metabolism and Pharmacokinetics, 1981
- Lisuride in parkinsonismAnnals of Neurology, 1981